# Nitrous oxide use and psychiatric disorders: a retrospective clinical cohort study on prevalence and patterns

**Authors:** Rebecca Paetow, Maike Franziska Dohrn, Michelle Finner-Prével, Leona Boesehans, Dariush Henning, Marcus Rust, Thomas Frodl

PMC · DOI: 10.3389/fpsyt.2025.1670500 · 2025-10-01

## TL;DR

This study found that a notable percentage of psychiatric patients have used nitrous oxide, with younger individuals being more likely to use it.

## Contribution

The study provides new insights into the prevalence and patterns of nitrous oxide use among psychiatric patients.

## Key findings

- 7.67% of psychiatric patients reported a history of nitrous oxide use.
- Younger age was statistically associated with nitrous oxide use.
- Most users obtained nitrous oxide from friends or social events.

## Abstract

Nitrous oxide (N2O) is used for anesthetic purposes but has gained popularity as a recreational substance. Despite its potentially severe adverse effects, knowledge about N2O use within psychiatric populations is limited. This study aimed to evaluate the life-time prevalence and patterns of N2O consumption among patients with psychiatric disorders.

A retrospective observational cohort study was conducted at the Department of Psychiatry, Psychotherapy and Psychosomatics of the Rheinisch-Westfälische Technische Hochschule (RWTH) Aachen University Hospital, involving assessments of N2O use lifetime prevalence among patients in various psychiatric settings over a six-month period in 2024. Further data on demographic characteristics and psychiatric diagnoses were collected from electronic patient records.

Out of 287 screened records, 22 patients (7.67%) reported a N2O use history, with a positive statistical relationship between younger age and positive lifetime prevalence (mean age: 28.14 ± 7.29 years, range 19–48 years, 6/22 female). Most users acquired N2O through low-threshold means such as friends or social events. The predominant psychiatric diagnoses among users included major depressive disorder, cannabis-related disorder and attention deficit and hyperactivity disorder.

This study highlights the concerning life-time prevalence of N2O use in a clinical psychiatric sample, emphasizing the need for increased awareness and education regarding its potential risks and side effects. Given the vulnerability of this population to substance-related issues, routine assessment for N2O use should be integrated into standard psychiatric evaluations.

## Linked entities

- **Chemicals:** nitrous oxide (PubChem CID 948), N2O (PubChem CID 948)
- **Diseases:** major depressive disorder (MONDO:0002009)

## Full-text entities

- **Diseases:** depressive disorder (MESH:D003866), attention deficit and hyperactivity disorder (MESH:D001289), psychiatric (MESH:D001523)
- **Chemicals:** N2O (MESH:D009609)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12522402/full.md

---
Source: https://tomesphere.com/paper/PMC12522402